• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Boehringer Ingelheim - Articles and news items

biosimilar

Boehringer Ingelheim’s bevacizumab biosimilar demonstrates bioequivalence

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

BI 695502, a bevacizumab biosimilar candidate to Avastin, is a monoclonal antibody that may slow or stop the growth of certain tumour types by preventing…

boeringer-ingelheim-nsclc

Reduced risk of NSCLC death seen in Boehringer Ingelheim’s head-to-head trial

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib…

collaboration-immune-oncology

Boehringer Ingelheim and ViraTherapeutics collaborate to boost immune-oncology pipeline

Industry news / 29 September 2016 / Niamh Louise Marriott, Digital Content Producer

Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development…

designation-orphan-drug

Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD…

metastatic breast cancer

Lilly and Boehringer Ingelheim take on metastatic breast cancer

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer…

ipf

First patient enrolled in IPF biomarker study of Ofev

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

INMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis…

consumer healthcare business

Sanofi and Boehringer Ingelheim reach next step in business swap

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

Sanofi and Boehringer Ingelheim have signed contracts to secure the exchange of Sanofi’s Merial and Boehringer Ingelheim’s consumer healthcare business…

jardiance

Jardiance reduces risk of progressive kidney disease in type 2 diabetes

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

Jardiance reduced the risk for new-onset or worsening kidney disease by 39% versus placebo in adults with type 2 diabetes with established CV disease…

jardiance

Jardiance data shows reduced risk of CV death in type 2 diabetes

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

New data for Jardiance (empagliflozin) show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes…

trulicity

New data for Trulicity and Tradjenta in type 2 diabetes

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

Lilly has announced new findings from separate studies of Trulicity and Tradjenta at the American Diabetes Association 76th Scientific Sessions…

boehringer ingelheim

Boehringer Ingelheim at ASCO: Oncology and Innovation

Blog, Z Homepage promo / 6 June 2016 / Victoria White, Digital Content Producer

We recently caught up with Dr Jörg Barth, Boehringer Ingelheim, to find out more about the company’s oncology pipeline and presence at ASCO….

Tiotropium found to improve lung function of children with asthma

Tiotropium found to improve lung function of children with asthma

Industry news / 18 May 2016 / Katie Sadler

New data has revealed tiotropium improves lung function in children who continue to experience asthma symptoms despite taking other maintenance therapies.

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +